|
A big, bad business 点肥成金不现实 Medical firms struggle to profit from weight-loss treatments 制药公司试图从减肥治疗中获利 OBESITY is an epidemic to some and an opportunity to others. 肥胖症对某些人来说是传染病，对别的一些人来说则是机遇。 More than two-thirds of Americans are overweight. 超过三分之二的美国人已经超重。 Find a way to battle the bulge and a huge profit might be made. 找个办法和肥胖对抗，说必定就此大赚一笔。 On February 22nd one pharmaceutical firm, Vivus, took a small step towards this goal. 找个办法和肥胖对抗，说必定就此大赚一笔。 A committee advising America s Food and Drug Administration recommended that itapprove Vivus s diet drug, Qnexa. 2月22日，Vivus制药公司朝着这个目标前进了一步。给美国食品药物管理局做咨询的一家委员会推荐，Vivus公司的减肥药Qnexa。 However, the pill s long-awaited final approval may not come until April, if at all. 但是，如果获得批准，该药品的漫长的最终肯定直到四月份才会到来。 | 
